Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner

References

• Hiemenz JW. Management of infections complicating allogeneic hematopoietic stem cell transplantation. Semin Hematol. 2009;46:289–312.
   PubMed Web of Science ®Google Scholar
• Ye Z, Wang Y, Xie HY, Zheng SS. Immunosuppressive effects of rat mesenchymal stem cells: involvement of CD4+CD25+ regulatory T cells. Hepatobiliary Pancreat Dis Int. 2008;7:608–14.
   PubMed Web of Science ®Google Scholar
• Soiffer R. Immune modulation and chronic graft-versus-host disease. Bone Marrow Transplant. 2008;42(Suppl 1):S66–9.
   Google Scholar
• Fowler DH. Shared biology of GVHD and GVT effects: potential methods of separation. Crit Rev Oncol Hematol. 2006;57:225–44.
   PubMed Web of Science ®Google Scholar
• Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112:4371–83.
   PubMed Web of Science ®Google Scholar
• Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139–70.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105:1815–22.
   PubMed Web of Science ®Google Scholar
• Wolff D, Steiner B, Hildebrandt G, Edinger M, Holler E. Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease. Curr Pharm Des. 2009;15:1974–97.
   PubMed Web of Science ®Google Scholar
• Wekerle T, Sykes M. Mixed chimerism and transplantation tolerance. Annu Rev Med. 2001;52:353–70.
   PubMed Web of Science ®Google Scholar
• Zhao RC, Liao L, Han Q. Mechanisms of and perspectives on the mesenchymal stem cell in immunotherapy. J Lab Clin Med. 2004;143:284–91.
   PubMedGoogle Scholar
• Nasef A, Chapel A, Mazurier C, Bouchet S, Lopez M, Mathieu N, .Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expr. 2007;13:217–26.
   PubMed Web of Science ®Google Scholar
• Ramasamy R, Tong CK, Seow HF, Vidyadaran S, Dazzi F. The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol. 2008;251:131–6.
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Klingebiel T, Lang P, Schumm M, Neu S, Geiselhart A, . Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant. 2001;27:777–83.
   PubMed Web of Science ®Google Scholar
• Beilhack A, Schulz S, Baker J, Beilhack GF, Wieland CB, Herman EI, . In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood. 2005;106:1113–22.
   PubMed Web of Science ®Google Scholar
• Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, . CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9:1144–50.
   PubMed Web of Science ®Google Scholar
• Skert C, Damiani D, Michelutti A, Patriarca F, Arpinati M, Fili C, . Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after Allo-SCT: results of a prospective study. Bone Marrow Transplant. 2009;44:729–37.
   PubMed Web of Science ®Google Scholar
• Reddy V, Winer AG, Eksioglu E, Meier-Kriesche HU, Schold JD, Wingard JR. Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:1014–21.
   PubMed Web of Science ®Google Scholar
• Jeong DC, Han CW, Jin JY, Kim DS, Choi IB, Kim WI, . Effectiveness of rotor off fraction in allogeneic murine bone marrow transplantation with complete disparity of major histocompatibility. Exp Hematol. 1999;27:1219–25.
   Google Scholar
• Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J Jr, Crawford JM, . An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation. I. The roles of minor H antigens and endotoxin. Blood. 1996;88:3230–9.
   PubMed Web of Science ®Google Scholar
• Fukui J, Inaba M, Ueda Y, Miyake T, Hosaka N, Kwon AH, . Prevention of graft-versus-host disease by intra-bone marrow injection of donor T cells. Stem Cells. 2007;25:1595–601.
   PubMed Web of Science ®Google Scholar
• Desbarats J, Seemayer TA, Lapp WS. Irradiation of the skin and systemic graft-versus-host disease synergize to produce cutaneous lesions. Am J Pathol. 1994;144:883–8.
   Google Scholar
• Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, . Bone-marrow transplantation (second of two parts). N Engl J Med. 1975;292:895–902.
   PubMed Web of Science ®Google Scholar
• Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW, . Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest. 1998;101:1835–42.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rey E, Gonzalez MA, Varela N, O’Valle F, Hernandez-Cortes P, Rico L, . Human adipose-derived mesenchymal stem cells reduce inflammatory and T-cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis. 2010;69:241–8.
   PubMed Web of Science ®Google Scholar
• Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D, . Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol. 2008;181:3933–46.
   PubMed Web of Science ®Google Scholar
• Di Ianni M, Del Papa B, De Ioanni M, Moretti L, Bonifacio E, Cecchini D, . Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol. 2008;36:309–18.
   PubMed Web of Science ®Google Scholar
• Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol. 2007;149:353–63.
   PubMed Web of Science ®Google Scholar
• Askenasy N, Kaminitz A, Yarkoni S. Mechanisms of T regulatory cell function. Autoimmun Rev. 2008;7:370–5.
   PubMed Web of Science ®Google Scholar
• Djouad F, Charbonnier LM, Bouffi C, Louis-Plence P, Bony C, Apparailly F, . Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells. 2007;25:2025–32.
   PubMed Web of Science ®Google Scholar
• English K, Barry FP, Mahon BP. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett. 2008;115:50–8.
   PubMed Web of Science ®Google Scholar
• Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, . Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009;15:42–9.
   PubMed Web of Science ®Google Scholar
• Najar M, Rouas R, Raicevic G, Id Boufker H, Lewalle P, Meuleman N, . Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy. 2009;11:570–83.
   PubMed Web of Science ®Google Scholar
• Tisato V, Naresh K, Girdlestone J, Navarrete C, Dazzi F. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia. 2007;21:1992–9.
   PubMed Web of Science ®Google Scholar
• Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Gray GS, Vallera DA. Coblockade of the LFA1:ICAM and CD28/ CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood. 1995;85:2607–18.
   PubMed Web of Science ®Google Scholar